Dynavax Technologies Reports 17.7% Revenue Growth in Q3 2025

Dynavax Technologies Corporation reported its financial results for the third quarter of 2025, revealing a total revenue of $94.9 million, a 17.7% increase from $80.6 million in the same period last year. The growth was primarily driven by a 13% rise in product revenue from HEPLISAV-B, which reached $90.0 million, up from $79.3 million in the prior year. For the nine months ending September 30, 2025, total revenues amounted to $258.5 million, a 26% increase compared to $205.2 million in the same period of 2024. However, the company reported a net loss of $50.5 million for the nine months, contrasting with a net income of $20.3 million in the previous year.

The company’s operating expenses for the third quarter were $73.6 million, slightly higher than $70.5 million in the same quarter of 2024. Research and development expenses surged by 33% to $19.1 million, reflecting increased investment in clinical trials, particularly for the shingles and plague vaccine programs. Selling, general, and administrative expenses decreased by 7% to $40.1 million, attributed to reduced marketing campaign expenses compared to the previous year. The company also recorded a significant allowance for doubtful accounts of approximately $11 million related to its contract with Clover Biopharmaceuticals, reflecting concerns over Clover's financial stability.

In terms of strategic developments, Dynavax announced a new agreement with Vaxart, Inc. in November 2025, granting an exclusive license to develop oral vaccines for various coronavirus infections. This agreement includes an upfront payment of $25 million and potential future milestone payments. The company also completed a share repurchase program, having repurchased approximately 16.6 million shares for about $200 million, which it views as a means to enhance shareholder value.

Operationally, Dynavax reported a cash and cash equivalents balance of $160.2 million as of September 30, 2025, up from $95.9 million at the end of 2024. The company’s total assets decreased to $946.5 million from $986.3 million at the end of the previous fiscal year, primarily due to a reduction in marketable securities. The company continues to focus on expanding its market share for HEPLISAV-B, which is expected to capture at least 60% of the U.S. hepatitis B vaccine market by 2030, following a universal vaccination recommendation from the CDC.

Looking ahead, Dynavax anticipates continued growth in HEPLISAV-B sales, driven by increased market penetration and favorable pricing strategies. However, the company also acknowledges the risks associated with its reliance on third-party manufacturers and the potential impact of regulatory changes on its operations. The management remains optimistic about the future, emphasizing the importance of advancing its clinical pipeline and maintaining strong financial health to support ongoing and future initiatives.